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BACKGROUND: Comorbidity and socioeconomic status (SES) may be related among cancer patients.
METHOD: Population-based cancer registry study among 72153 patients diagnosed during 1997–2006.
RESULTS: Low SES patients had 50% higher risk of serious comorbidity than those with high SES. Prevalence was increased for
each cancer site. Low SES cancer patients had significantly higher risk of also having cardiovascular disease, chronic obstructive
pulmonary diseases, diabetes mellitus, cerebrovascular disease, tuberculosis, dementia, and gastrointestinal disease. One-year survival
was significantly worse in lowest vs highest SES, partly explained by comorbidity.
CONCLUSION: This illustrates the enormous heterogeneity of cancer patients and stresses the need for optimal treatment of cancer
patients with a variety of concomitant chronic conditions.
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People of a lower socioeconomic status (SES) generally have
poorer health status and higher mortality than people of higher
SES (Jemal et al, 2008; Mackenbach et al, 2008), also with respect
to cancer, with in general higher incidence rate of all cancers
combined among people from lower socioeconomic groups
(Dalton et al, 2008). A differential distribution of known risk
factors for specific neoplasms between SES groups seems a likely
explanation for the above inequalities. For example, the prevalence
of smokers has become higher among lower classes (Lahelma et al,
1997; Stronks et al, 1997), probably resulting in higher rates
of cancer of the lung, larynx, mouth, pharynx, oesophagus, and
bladder (Siemiatycki et al, 1995; Stellman and Resnicow, 1997;
Tyczynski et al, 2003). However, smoking is not only related to
cancer but also to chronic obstructive pulmonary diseases
(COPD) and cardiovascular diseases (Doll et al, 1994). Hence,
the high prevalence of comorbidity among lung cancer patients
(Janssen-Heijnen et al, 1998). Socioeconomic status may thus
be associated with comorbidity among cancer patients. Thus,
medical doctors are presented with a heterogeneous group of
cancer patients, for whom appropriate individual treatment must
be chosen, taking concomitant conditions into account (Ayanian
et al, 2003; Lash et al, 2003; Janssen-Heijnen et al, 2004; Lemmens
et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005).
We studied in a large population-based group of cancer patients
the prevalence of comorbidity according to SES, not only by
number of concomitant diseases, but also for specific diseases that
affect patients with the various tumour sites.
MATERIALS AND METHODS
The Eindhoven Cancer Registry records data on all patients newly
diagnosed with cancer in the south of the Netherlands (2.4 million
inhabitants, 15% of the Dutch population); it also records serious
comorbidity according to an adaptated list (Charlson et al, 1987).
Chronic obstructive pulmonary diseases, cardio- and cerebro-
vascular diseases, peripheral arterial disease, other malignancies,
and diabetes mellitus, connective tissue diseases, rheumatoid
arthritis, kidney, bowel, and liver diseases, dementia, tuberculosis
and other chronic infections were also recorded. For most analyses
peripheral arterial disease was included in the cardiovascular
diseases, although gastrointestinal diseases were grouped (gastric
diseases, Crohn’s disease, ulcerative colitis, liver cirrhosis, and
hepatitis). Comorbidity was defined as life-shortening disease that
was present at the time of cancer diagnosis and/or received
treatment or surveillance. Trained registry personnel actively
collect data on diagnosis, staging, and treatment from the medical
records after notification by pathologists and medical registration
offices. Previous admissions, letters from and to general practi-
tioners and other specialists, the medical history and preoperative
screening were used as sources.
Patients with cancer of the oesophagus, stomach, colon or
rectum, pancreas, lung, melanoma, breast, cervix uteri, corpus
uteri, ovary, prostate, bladder, kidney, and non-Hodgkin’s
lymphoma (NHL), newly diagnosed between 1997 and 2006
(n¼72153), were included in this study; cancers diagnosed at
autopsy (n¼369) were excluded.
Statistics Netherlands developed an indicator of SES, using
individual fiscal data on the economic value of the home
and household income, and is provided at aggregated level
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Socioeconomic status was categorised as low (deciles 1–3),
medium (deciles 4–7), or high social class (deciles 8–10), and a
separate class for postal codes for a long-term care providing
institution (such as a nursing home; van Duijn and Keij, 2002).
We calculated the distribution of cancer patients across socio-
economic strata according to tumour localisation, also by gender
and age. Patients for whom the SES was unknown (n¼766, 1%) or
for whom the postal code included a care providing institution
(n¼3569, 5%), as well as those with unknown comorbidity
(n¼8399, 12%) were excluded from the analyses of SES and
comorbidity. Differences in distribution were tested with the
w
2 test. Logistic regression analyses of the odds of having a specific
concomitant disease were performed age- and gender-adjusted for
all tumour sites combined, and according to tumour site for four
concomitant diseases separately; cardiovascular disease, COPD,
diabetes mellitus, and gastrointestinal disease. Statistical
significance of an overall effect of SES on the prevalence of a
specific condition was tested using the w
2-likelihood ratio test.
Crude 1-year survival rates were calculated for all studied tumours
combined and for the most important tumour sites separately.
Cox’s regression models were used to compute multivariate rates
(hazard ratio¼HR) and 95% confidence intervals (95% CI).
The relative contribution (%) of adding comorbidity to the model
was calculated as follows: ((HR model A HR model B)/(HR model
A 1)) 100, where A is the basic model (age- and gender-
adjusted) and in model B comorbidity is added to model A.
All statistical analyses were performed using SAS V9.12 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Male cancer patients were older than female patients (Table 1), the
median age being 69 and 64 years, respectively (Po0.0001). At the
time of the diagnosis of the cancer 71% of male and 58% of female
cancer patients had at least one concomitant disease. The most
frequent concomitant condition for males with cancer was
cardiovascular disease (23%), for women hypertension (20%),
among cancer patients older than 70 the prevalence of these
diseases was 34% and 31%, respectively. In the subgroup of cancer
patients with two or more concomitant diseases, the most frequent
combination of diseases among males was cardiovascular
disease with hypertension (14%) and in females diabetes with
hypertension (21%).
The proportion of patients by SES varied for the different
tumour sites (Table 2). Patients under age 70 with stomach, lung,
bladder, or cervical cancer more often had low SES. High SES
was more frequent among patients with melanoma or breast,
colorectal, or prostate cancer in this age group.
Among patients aged 70þ with cancer of the oesophagus,
stomach, or lung, low SES was clearly over-represented. High SES
was more frequent among patients with prostate cancer or NHL.
For all tumour localisations the proportion of patients without
comorbidity was highest in the high SES group (Figure 1).
Table 1 Description of all cancer patients diagnosed with selected
tumours between 1997 and 2006 in the Eindhoven Cancer Registry
Males Females Total
n % n % n %
Tumour localisation
Oesophagus 1079 3 398 1 1477 2
Stomach 1723 5 1032 3 2755 4
Colorectal 6815 19 6014 17 12829 18
Pancreas 907 2 849 2 1756 2
Lung 9354 26 3591 10 12945 18
Melanoma 1405 4 1899 5 3304 5
Breast — 14859 41 14859 20
Cervix uteri — 725 2 725 1
Corpus uteri — 2128 6 2128 3
Ovary — 1540 4 1540 2
Prostate 9987 27 — 9987 14
Kidney 1201 3 806 2 2007 3
Urinary bladder 2306 6 679 2 2985 4
Non-Hodgkin’s lymphoma 1846 5 1413 4 3259 4
Age
o45 1156 3 3884 11 5040 7
45–59 6624 18 10578 29 17202 24
60–74 18984 52 13142 37 32126 44
475 9859 27 8329 23 18188 25
SES
Low 9518 26 9953 28 19471 27
Intermediate 14309 39 13824 38 28133 39
High 10812 30 9741 27 20553 28
Institution 1569 4 2032 6 3601 5
Unknown 415 1 383 1 798 1
Comorbidity
Number of concomitant diseases
0 10688 29 14826 41 25514 35
1 10775 29 9353 26 20128 28
42 10992 30 7050 20 18042 25
Unknown 4168 11 4704 13 8872 12
Concomitant disease
a
Previous cancer 4460 12 3565 10 7977 11
Cardiovascular disease 8353 23 3854 11 12127 17
Peripheral arterial disease 3445 9 1358 4 4767 7
COPD 5347 15 2674 7 7994 11
Hypertension 6367 17 7184 20 13462 19
Diabetes mellitus 3586 10 3482 10 7026 10
Cerebrovascular disease 1754 5 1044 3 2779 4
Tuberculosis 553 2 409 1 947 1
Central nervous system
b 221 1 354 1 568 1
Gastrointestinal disease 2629 7 1294 4 3900 5
Other diseases 925 3 1078 3 1987 3
Total 36623 50 35933 50 72556 100
Abbreviations: COPD¼chronic obstructive pulmonary diseases; SES¼socioeco-
nomic status.
aPatients may suffer from more than one condition.
bDementia in 96%
of these patients.
Table 2 Distribution of cancer patients newly diagnosed in 1997–2006
according to gender, age and socioeconomic status (SES)
Males Females
o70 70+ o70 70+
Tumour
localisation
No. of
patients
% low
SES
No. of
patients
% low
SES
No. of
patients
% low
SES
No. of
patients
% low
SES
Oesophagus 589 23 342 37 170 30 161 43
Stomach 767 26 719 37 386 31 465 44
Colorectal 3176 21 2662 32 2266 24 2630 40
Pancreas 433 24 339 36 325 28 374 44
Lung 4498 29 3827 38 2226 35 923 50
Melanoma 563 15 169 33 729 16 194 43
Breast — — — — 9070 21 3094 42
Cervix uteri — — — — 476 37 120 43
Corpus uteri — — — — 1189 25 576 42
Ovary — — — — 875 23 438 42
Prostate 3930 20 4149 30 — — — —
Kidney 639 22 392 32 372 31 300 41
Urinary
bladder
855 25 1027 33 216 32 308 40
Non-Hodgkin’s
lymphoma
1060 21 575 31 703 25 514 42
Total of
these sites
16510 23 14201 34 19003 24 10097 42
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lower SES groups (Po0.001), which had a significantly higher
risk of cardiovascular disease (ORlow vs high SES¼1.4, 95% CI:
1.3–1.5), COPD (OR¼1.8 (1.7–1.9)), diabetes mellitus (OR¼1.5
(1.4–1.6)), cerebrovascular disease (OR¼1.5 (1.4–1.7)), tuber-
culosis (OR¼1.3 (1.1–1.6)), dementia (OR¼1.3 (1.0–1.8)),
gastrointestinal disease (OR¼1.5 (1.4–1.6)), and two or more
concomitant conditions (OR¼1.8 (1.7–1.9)) in addition to their
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Figure 1 Number of concomitant diseases among cancer patients diagnosed in 1997–2006 in the Southeastern Netherlands. *Distribution of number of
concomitant diseases significantly different from the highest socioeconomic status category.
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one other serious concomitant disease was 50% higher in the low
SES than in the high SES group (OR¼1.5 (1.4–1.6)).
For four concomitant conditions we stratified by tumour
localisation (Figure 2). The risk of cardiovascular disease among
low compared with high SES patients was significantly higher
(1.4–1.6 times) for patients with stomach, colorectal, lung, breast,
prostate, and bladder cancer. The risk of COPD was elevated
among low SES patients with cancer of the stomach, colorectum,
pancreas, lung, breast, corpus uteri, prostate, and kidney
(OR’s ranging from 1.4 to 2.2). The risk of diabetes mellitus
was highest among people from low SES with breast cancer
(OR¼2.0 (1.2–2.4)) and the risk of gastrointestinal diseases
was highest among patients with oesophageal cancer (OR¼2.0
(1.2–3.4)).
Crude 1-year survival of cancer patients from lower SES was
worse compared with the highest SES for all tumour sites
combined and for the major sites separately (Table 4). The age-
adjusted risk of death was significantly elevated for both men
(HRlow vs high SES¼1.40, 95% CI: 1.3–1.4) and women (HR 1.40
(1.3–1.5)). Adding comorbidity to the model reduced HR to 1.35
Table 3 Risk of specific concomitant diseases according to SES adjusted
for age and gender among cancer patients diagnosed in 1997–2006
SES
Concomitant disease Low Intermediate High P
a
Previous cancer 1.01 0.99 1.00 0.7
Cardiovascular disease 1.42
b 1.23
b 1.00 0.0001
COPD 1.81
b 1.37
b 1.00 0.0001
Hypertension 0.98 1.03 1.00 0.2
Diabetes mellitus 1.52
b 1.32
b 1.00 0.0001
Cerebrovascular disease 1.53
b 1.27
b 1.00 0.0001
Tuberculosis 1.34
b 1.17 1.00 0.01
Central nervous system 1.34
b 1.05 1.00 0.05
Gastrointestinal 1.48
b 1.27
b 1.00 0.0001
Other 1.22
b 1.10 1.00 0.01
1 or more concomitant disease 1.50
b 1.24
b 1.00 0.0001
2 or more concomitant diseases 1.80
b 1.36
b 1.00 0.0001
Abbreviations: COPD¼chronic obstructive pulmonary diseases; SES¼socio-
economic status.
aP for overall effect of SES (w
2-likelihood ratio).
bConfidence
interval does not include 1.00.
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Figure 2 Risk of four concomitant diseases among cancer patients with the lowest socioeconomic status (SES) compared with those with the highest SES
(¼reference, 1.00) according to tumour localisation with adjustment for age and gender. *95% confidence interval does not include 1.00; # No reliable
estimate because o5 cases in reference category.
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comorbidity in explaining the inequality in 1-year survival varied
from 0% for lung cancer to 33% among female colorectal cancer
patients.
DISCUSSION
To our knowledge, this is the first large population-based study to
demonstrates the impact of SES on the prevalence of concomitant
diseases among cancer patients, with increased prevalence of
comorbidity in lower socioeconomic strata for each type of cancer.
Cancer patients with low SES had a 50% higher risk of suffering
from at least one other serious disease compared with those with
high SES. The prevalence of comorbidity was significantly higher
with newly diagnosed cancer of lower compared with higher SES
for all 14 cancer sites studied. The diseases significantly related to
SES among cancer patients were cardiovascular disease, COPD,
diabetes mellitus, cerebrovascular disease, tuberculosis, diseases of
the central nervous system, and gastrointestinal disease. Although
both the prevalence of comorbidity and the proportional distri-
bution of SES vary significantly among tumour types, the gradient
of more comorbidity from high to low SES was apparent among
all tumour types.
Smoking is probably responsible for the higher risk of
cardiovascular disease, COPD, and cerebrovascular disease among
low SES groups (Doll et al, 1994; Stellman and Resnicow, 1997).
This is confirmed by the higher prevalence of those diseases
among patients with smoking-related tumours: cancers of the
stomach, lung, bladder, and kidney (Janssen-Heijnen et al, 1998;
Koppert et al, 2004). Diabetes was more frequent among low SES
for patients with cancers of the colorectum, pancreas, lung, breast,
corpus uteri or prostate, or melanoma or NHL. Diabetes has been
linked to pancreas cancer (Jain et al, 1991; Kalapothaki et al, 1993)
either as a risk factor or as the clinical manifestation of the cancer
itself (Warshaw and Fernandez-del Castillo, 1992). Diabetes has
also been associated with an increased risk for breast (Xue and
Michels, 2007), endometrial (Parazzini et al, 1991), and colorectal
cancer (Polednak, 2006) probably because of a relation with
obesity (Reeves et al, 2007). Substantial evidence exists for the
association of obesity with low SES (Sobal and Stunkard, 1989;
Wardle et al, 2002; McLaren, 2007).
The prevalence of gastrointestinal diseases was highest for low
SES patients with oesophageal, colorectal, lung, breast, prostate or
kidney cancer, or NHL. Oesophageal cancer has also been
associated with gastrointestinal diseases (Koppert et al, 2004).
A lower consumption of vegetables, fruit, and fibres, which may
protect from oesophageal (Tzonou et al, 1996; Terry et al, 2001b)
and colorectal cancer (Pietinen et al, 1999; Michels et al, 2000;
Voorrips et al, 2000; Terry et al, 2001a; Bueno-de-Mesquita et al,
2002; Flood et al, 2002), has been reported among lower SES
(Wallstrom et al, 2000; Hulshof et al, 2003; Wardle and Steptoe,
2003).
We used an indicator of SES based on the postal code of
a residential area. This aggregate covers a very small geo-
graphical area, and thus represents a reliable approximation of
individual SES. Furthermore, routinely collected income tax
data (no questionnaires or interviews) have been found to
provide reliable estimates of household income. Previous studies
have proven that socioeconomic differences based on neigh-
bourhood data tend to reflect such differences well at the
individual level (Bos et al, 2000, 2001; Smits et al, 2001).
Furthermore, this objective measure of SES is also applicable to
older women (born before 1955), whose occupation or education
does not always properly reflect their social class (Berkman and
Macintyre, 1997).
Previously, we found that patients with comorbidity were
often treated less aggressively, if alternative treatment strategies
were available. Except for patients with a tumour with poor
survival, comorbidity has an independent prognostic effect
(Janssen-Heijnen et al, 2005). This negative impact of comorbidity
on survival of cancer might have several mechanisms: the
increased risk of death due to the comorbid condition itself, more
contra-indications for the cancer treatment, more indications for
dose reduction and a higher rate of treatment-related complica-
tions such as infections and cardiovascular events. In several of
our recent studies, the adverse effects of comorbidity on survival
appeared to be independent of treatment, so less aggressive
treatment could not (fully) account for the observed differences
in survival between patients with and without comorbidity
(Post et al, 2001; Lemmens et al, 2005; Louwman et al, 2005;
van Spronsen et al, 2005; Houterman et al, 2006). As SES
represents a combination of lifestyle, health, and risk of
suboptimal treatment, cancer patients with comorbidity could
also (partly) explain the poorer prognosis. Although an in-depth
study remains necessary to reveal whether stage at diagnosis
and treatment contributed to the SES gradient in survival, also
for longer survival periods, our preliminary analyses demonstrated
a clear gradient in 1-year survival rates, which could partly
be attributed to comorbidity.
Table 4 Crude survival, risk of death, and contribution of comorbidity to risk of death according to tumour site and SES among cancer patients diagnosed
in 1997–2006
1-year survival rate (%) Model A
a Model B
a
Relative contribution
Low SES Inter-mediate High SES HR
c (95% CI) HR
c (95% CI) comorbidity
b
Males
Colorectum 72 78 78 1.13 (1.0–1.3) 1.10 (1.0–1.3) 23%
Lung 36 39 41 1.11 (1.0–1.2) 1.11 (1.0–1.2) 0%
Prostate 90 94 95 1.47 (1.2–1.8) 1.36 (1.1–1.7) 22%
Total
d 59 66 70 1.40 (1.3–1.5) 1.35 (1.3–1.4) 12%
Females
Colorectum 74 78 79 1.09 (0.9–1.3) 1.06 (0.9–1.2) 33%
Lung 41 42 46 1.09 (1.0–1.2) 1.09 (1.0–1.2) 0%
Breast 94 97 98 1.68 (1.3–2.2) 1.56 (1.2–2.0) 18%
Total
d 74 81 84 1.40 (1.3–1.5) 1.34 (1.3–1.4) 15%
aModel A: adjusted for age, Model B: adjusted for age and the presence of concomitant diseases (yes vs no).
b((HR model A (HR model A+comorbidity))/(1 HR model
A)) 100.
cHazard Ratio (HR) of lowest socioeconomic status (SES) group compared with highest (¼reference).
dAll studied sites combined (oesophagus, stomach,
colorectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, kidney, urinary bladder, non-Hodgkin’s lymphoma).
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by tumour type and a higher risk of concomitant disease
among patients from lower SES. Given the aetiology of the
type of tumours as well as the aetiology of the concomitant
diseases that occur more frequently among patients from low
SES background, a lot can probably be gained from preventive
measures related to lifestyle (such as smoking and obesity).
Considering survival is worse for patients of low SES, our
results stress the need for reduction of socioeconomic differences
in health.
ACKNOWLEDGEMENTS
Supported by a grant from the Dutch Cancer Society (IKZ 2000-2260).
REFERENCES
Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM,
Cress RD, O’Connor LC, West DW, Allen ME, Wolf RE, Wright WE
(2003) Use of adjuvant chemotherapy and radiation therapy
for colorectal cancer in a population-based cohort. J Clin Oncol 21:
1293–1300
Berkman LF, Macintyre S (1997) The measurement of social class in health
studies: old measures and new formulations. IARC Sci Publ 138:5 1 – 6 4
Bos V, Kunst AE, Mackenbach JP (2000) Nationale gegevens over sociaal-
economische sterfteverschillen op basis van informatie over kleine
geografische eenheden. Verslag aan de programmacommissie Sociaal-
economische gezondheidsverschillen II. Instituut Maatschappelijke
Gezondheidszorg, Erasmus Universiteit: Rotterdam
Bos V, Kunst AE, Mackenbach JP (2001) De omvang van sociaal-
economische sterfteverschillen gemeten op buurtniveau: vergelijking
met schattingen op basis van informatie op individueel niveau.
In Sociaal-economische gezonheidsverschillen: Van verklaren naar
verkleinen, Stronks K (ed) Vol. 5, pp 8–20. Zon/MW: Den Haag
Bueno-de-Mesquita HB, Ferrari P, Riboli E (2002) Plant foods and the risk
of colorectal cancer in Europe: preliminary findings. IARC Sci Publ 156:
89–95
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 40: 373–383
Dalton SO, Schuz J, Engholm G, Johansen C, Kjaer SK, Steding-Jessen M,
Storm HH, Olsen JH (2008) Social inequality in incidence of and survival
from cancer in a population-based study in Denmark, 1994–2003:
summary of findings. Eur J Cancer 44(14): 2074–2085
Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality
in relation to smoking: 40 years’ observations on male British doctors.
Br Med J 309: 901–911
Flood A, Velie EM, Chaterjee N, Subar AF, Thompson FE, Lacey Jr JV,
Schairer C, Troisi R, Schatzkin A (2002) Fruit and vegetable intakes and
the risk of colorectal cancer in the Breast Cancer Detection Demonstra-
tion Project follow-up cohort. Am J Clin Nutr 75: 936–943
Houterman S, Janssen-Heijnen ML, Hendrikx AJ, Berg HA, Coebergh JW
(2006) Impact of comorbidity on treatment and prognosis of prostate
cancer patients: A population-based study. Crit Rev Oncol Hematol 58:
60–67
Hulshof KF, Brussaard JH, Kruizinga AG, Telman J, Lowik MR (2003)
Socio-economic status, dietary intake and 10 y trends: the Dutch
National Food Consumption Survey. Eur J Clin Nutr 57: 128–137
Jain M, Howe GR, St Louis P, Miller AB (1991) Coffee and alcohol as
determinants of risk of pancreas cancer: a case-control study from
Toronto. Int J Cancer 47: 384–389
Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW,
Maas HA, Coebergh JW (2005) Prognostic impact of increasing age
and co-morbidity in cancer patients: a population-based approach.
Crit Rev Oncol Hematol 55: 231–240
Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA,
Coebergh JW (1998) Prevalence of co-morbidity in lung cancer patients
and its relationship with treatment: a population-based study. Lung
Cancer 21: 105–113
Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ,
Coebergh JW (2004) Effect of comorbidity on the treatment and
prognosis of elderly patients with non-small cell lung cancer. Thorax
59: 602–607
Jemal A, Thun MJ, Ward EE, Henley SJ, Cokkinides VE, Murray TE (2008)
Mortality from leading causes by education and race in the United States,
2001. Am J Prev Med 34: 1–8
Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A,
Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes
mellitus, and cholelithiasis as risk factors for pancreatic carcinoma.
Cancer Causes Control 4: 375–382
Koppert LB, Janssen-Heijnen ML, Louwman MW, Lemmens VE,
Wijnhoven BP, Tilanus HW, Coebergh JW (2004) Comparison of
comorbidity prevalence in oesophageal and gastric carcinoma patients:
a population-based study. Eur J Gastroenterol Hepatol 16: 681–688
Lahelma E, Rahkonen O, Berg MA, Helakorp S, Prattala R, Puska P,
Uutela A (1997) Changes in health status and health behavior among
Finnish adults 1978–1993. Scand J Work Environ Health 23(Suppl 3):
85–90
Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA (2003) Multiple
informants: a new method to assess breast cancer patients’ comorbidity.
Am J Epidemiol 157: 249–257
Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van
Driel OJ, Coebergh JW (2005) Co-morbidity leads to altered treatment
and worse survival of elderly patients with colorectal cancer. Br J Surg 92:
615–623
Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der
Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive
treatment and inferior prognosis for breast cancer patient with
comorbidity: a population-based study. Eur J Cancer 41: 779–785
Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, Leinsalu M,
Kunst AE (2008) Socioeconomic inequalities in health in 22 European
countries. N Engl J Med 358: 2468–2481
McLaren L (2007) Socioeconomic status and obesity. Epidemiol Rev 29:
29–48
Michels KB, Edward G, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS,
Colditz GA, Speizer FE, Willett WC (2000) Prospective study of fruit and
vegetable consumption and incidence of colon and rectal cancers. J Natl
Cancer Inst 92: 1740–1752
Parazzini F, La Vecchia C, Bocciolone L, Franceschi S (1991) The
epidemiology of endometrial cancer. Gynecol Oncol 41: 1–16
Pietinen P, Malila N, Virtanen M, Hartman TJ, Tangrea JA, Albanes D,
Virtamo J (1999) Diet and risk of colorectal cancer in a cohort of Finnish
men. Cancer Causes Control 10: 387–396
Polednak AP (2006) Comorbid diabetes mellitus and risk of death after
diagnosis of colorectal cancer: a population-based study. Cancer Detect
Prev 30: 466–472
Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW (2001)
The independent prognostic value of comorbidity among men aged
o75 years with localized prostate cancer: a population-based study.
BJU Int 87: 821–826
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer
incidence and mortality in relation to body mass index in the Million
Women Study: cohort study. Br Med J 335: 1134
Siemiatycki J, Krewski D, Franco E, Kaiserman M (1995) Associations
between cigarette smoking and each of 21 types of cancer: a multi-site
case-control study. Int J Epidemiol 24: 504–514
Smits J, Keij I, Westert G (2001) Effecten van sociaal-economische status
van kleine, middelgrote en grote geografische eenheden op de sterfte.
Mndstat bevolking 11: 4–10
Sobal J, Stunkard AJ (1989) Socioeconomic status and obesity: a review
of the literature. Psychol Bull 105: 260–275
Stellman SD, Resnicow K (1997) Tobacco smoking, cancer and social class.
IARC Sci Publ 229–250
Stronks K, van de Mheen HD, Looman CW, Mackenbach JP (1997)
Cultural, material, and psychosocial correlates of the socioeconomic
gradient in smoking behavior among adults. Prev Med 26: 754–766
Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L,
Wolk A (2001a) Fruit, vegetables, dietary fiber, and risk of colorectal
cancer. J Natl Cancer Inst 93: 525–533
Socioeconomic status and comorbidity
WJ Louwman et al
1747
British Journal of Cancer (2010) 103(11), 1742–1748 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yTerry P, Lagergren J, Hansen H, Wolk A, Nyren O (2001b) Fruit and
vegetable consumption in the prevention of oesophageal and cardia
cancers. Eur J Cancer Prev 10: 365–369
Tyczynski JE, Bray F, Parkin DM (2003) Lung cancer in Europe in 2000:
epidemiology, prevention, and early detection. Lancet Oncol 4: 45–55
Tzonou A, Lipworth L, Garidou A, Signorello LB, Lagiou P, Hsieh C,
Trichopoulos D (1996) Diet and risk of esophageal cancer by histologic
type in a low-risk population. Int J Cancer 68: 300–304
van Duijn C, Keij I (2002) Sociaal-economische status indicator op
postcode niveau. Maandstatistiek van de bevolking 50: 32–35
van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG,
Coebergh JW (2005) Independent prognostic effect of co-morbidity in
lymphoma patients: results of the population-based Eindhoven Cancer
Registry. Eur J Cancer 41: 1051–1057
Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, Hermus RJ,
van den Brandt PA (2000) Vegetable and fruit consumption and risks of
colon and rectal cancer in a prospective cohort study: The Netherlands
Cohort Study on Diet and Cancer. Am J Epidemiol 152: 1081–1092
Wallstrom P, Wirfalt E, Janzon L, Mattisson I, Elmstahl S, Johansson U,
Berglund G (2000) Fruit and vegetable consumption in relation to risk
factors for cancer: a report from the Malmo Diet and Cancer Study.
Public Health Nutr 3: 263–271
Wardle J, Steptoe A (2003) Socioeconomic differences in attitudes
and beliefs about healthy lifestyles. J Epidemiol Community Health 57:
440–443
Wardle J, Waller J, Jarvis MJ (2002) Sex differences in the asso-
ciation of socioeconomic status with obesity. Am J Public Health 92:
1299–1304
Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma.
N Engl J Med 326: 455–465
Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast
cancer: a review of the current evidence. Am J Clin Nutr 86: s823–s835
Socioeconomic status and comorbidity
WJ Louwman et al
1748
British Journal of Cancer (2010) 103(11), 1742–1748 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y